Aspirin Resistance Reversibility in Diabetic Patients
- Registration Number
- NCT01935193
- Lead Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Brief Summary
The aim of the study is assessing the prevalence of aspirin resistance in a cohort of diabetic patients. Those found resistant has been undergone pharmacological tests using different drug formulations to investigate the reversibility of aspirin resistance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- diabete mellitus type 2
- asa since 30 days at least
- plts >150000 and <450000
Exclusion Criteria
- recent ACS (within 30 days)
- anticoagulant therapy
- haemorragic diathesis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description asa resistant lysine acetylsalicylate asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
- Primary Outcome Measures
Name Time Method platelets aggregation assessed by two tests (PFA100 and VerifyNow) 24 hours diabetic patients found aspirin resistant receive and infusion of 288 mg of lysine acetylsalicylate and they are tested again 24 h after the infusion to investigate if aspirin resistance have been reversed.
- Secondary Outcome Measures
Name Time Method stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate 1 month
Trial Locations
- Locations (1)
San Giovanni Battista Hospital
🇮🇹Torino, Italy